Inari Medical, Inc. Stock Price, News & Analysis

Inari Medical, Inc. (NASDAQ: NARI) announced the appointment of Robert Warner to its board of directors as a member of the Audit Committee. Warner brings extensive experience, having served in various executive roles at Alcon, including President of the U.S. and Canada. His leadership is anticipated to add significant value as Inari advances its mission to treat patients with venous diseases. The company specializes in minimally-invasive devices for treating deep vein thrombosis and pulmonary embolism, which are FDA-cleared and CE Mark approved.

Inari Medical reported strong financial results for Q4 2021, generating revenue of $83.2 million, a 71% increase year-over-year. For the full year, revenue reached $277 million, up 98% from 2020. The company treated 7,700 patients, a 15% rise from Q3, with over 90% from non-COVID cases. Gross margin for Q4 was 90.1%, while operating expenses rose to $73.2 million. Net income for Q4 was $1.1 million, down from $7 million in Q4 2020. Looking ahead, Inari provides 2022 revenue guidance of $350 million to $360 million.

On February 15, 2022, Inari Medical announced the enrollment of the first patient in the PEERLESS trial, a randomized controlled study comparing the FlowTriever system with catheter-directed thrombolysis for treating pulmonary embolism (PE). The trial aims to enroll 550 patients across 60 centers in the U.S. and Europe, with additional patients in a registry cohort for those contraindicated for thrombolytics. Experts express optimism that the trial will enhance understanding of PE treatment and generate valuable clinical data.

Inari Medical (NASDAQ: NARI) will release its fourth quarter and full-year financial results on February 23, 2022. The company specializes in innovative medical devices for treating venous diseases.

Following the results announcement, Inari will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent highlights. Interested parties can access the live call via designated numbers or through the company's investor relations website.

Inari Medical, Inc. (NASDAQ: NARI), a medical device company specializing in treatments for venous diseases, announced its participation in two upcoming investor conferences. The first is the BTIG MedTech Conference on February 15, 2022, at 12:00 p.m. Eastern Time. The second is the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:00 p.m. Eastern Time, with a live audio webcast available. Inari develops innovative catheter-based devices for the non-surgical treatment of conditions like deep vein thrombosis and pulmonary embolism.

Inari Medical (NASDAQ: NARI) reported preliminary unaudited revenue for Q4 2021, indicating a range of $82.8 to $83.3 million, marking a 14% sequential and 71% year-over-year increase. For the full year 2021, revenue is expected between $276.6 and $277.1 million, representing an approximate 98% rise over 2020. The company treated 7,700 patients in Q4, a 15% increase from Q3. Inari continues to focus on non-COVID patients, with over 200 U.S. sales territories established.

Inari Medical, Inc. (NASDAQ: NARI) is set to present at the 40^th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:00 p.m. Eastern Time. The presentation will focus on the company's innovative products designed for treating venous diseases, emphasizing its minimally-invasive catheter-based mechanical thrombectomy devices. These devices, the ClotTriever and FlowTriever systems, are FDA-cleared and CE-marked for the removal of clots from peripheral blood vessels, specifically targeting conditions like deep vein thrombosis and pulmonary embolism.

Inari Medical (NASDAQ: NARI) reported a record revenue of $72.9 million for Q3 2021, marking a 15% sequential and 88% year-over-year increase. The FDA cleared the ClotTriever Bold Thrombectomy Catheter, expanding treatment options for patients with advanced DVT. The company's gross profit reached $65.9 million, yielding a gross margin of 90.3%. However, operating expenses surged to $68.6 million, primarily due to increased personnel costs and stock-based compensation. Inari's cash reserves stand at $168.6 million. The revenue guidance for 2021 was raised to $266 to $268 million.

Inari Medical, Inc. (NASDAQ: NARI) announced promising interim results from the FlowTriever Outcomes Registry (FLASH) involving 500 pulmonary embolism patients. At 48 hours post-procedure, the major adverse event rate was 1.4% and mortality rate a low 0.2%, with no device-related complications. Significant improvements were observed in cardiac function and quality of life at 6 months. The study highlights FlowTriever as a leading therapy for intermediate and high-risk PE patients, demonstrating safety and effectiveness while minimizing hospital resource use.